Personalis
Provider of personalized genomic testing and analytics for oncology. Offers ultrasensitive, tumor-informed circulating tumor DNA (ctDNA) assays and comprehensive tumor sequencing to support minimal residual disease (MRD) detection, therapy selection, biomarker discovery, and biopharma clinical studies. Operates a CLIA/CAP/NYSDOH-accredited laboratory with a quality management system aligned to ISO13485 standards and collaborates with biopharma partners to integrate genomic assays into clinical development.
Industries
Nr. of Employees
medium (51-250)
Personalis
Patents
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12516385-B2
View Details
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12516385-B2
View DetailsProducts
Personalized ultrasensitive ctDNA MRD assay
Tumor‑informed circulating tumor DNA assay designed to detect molecular residual disease and early recurrence at ultra-low allele fractions by leveraging tumor sequencing to create personalized panels.
Comprehensive tumor genomic profiling (deep sequencing)
High‑depth sequencing assay that interrogates the full set of cancer genes to support therapy matching and molecular characterization.
Biomarker analysis platform for neoantigen identification
Analytical platform and workflows to identify biomarkers and candidate neoantigens to enable personalized vaccine development and other targeted immunotherapies.
NeXT Personal® Dx
An ultra-sensitive tumor-informed liquid biopsy assay designed to detect molecular residual disease (MRD) at ultra-low levels, track responses to therapy, and identify clinically relevant variants.
ImmunoID NeXT
ImmunoID NeXT combines multiple biomarker assays into one, simultaneously solving logistical and technical problems for clinical trial sponsors by elucidating tumor-immune interactions from a single sample.
ACE ImmunoID
ACE ImmunoID is an analytically-validated whole exome and transcriptome sequencing platform using matched tumor and normal samples, developed for use with our RUO neoantigen prediction analysis pipeline.
Personalized ultrasensitive ctDNA MRD assay
Tumor‑informed circulating tumor DNA assay designed to detect molecular residual disease and early recurrence at ultra-low allele fractions by leveraging tumor sequencing to create personalized panels.
Comprehensive tumor genomic profiling (deep sequencing)
High‑depth sequencing assay that interrogates the full set of cancer genes to support therapy matching and molecular characterization.
Biomarker analysis platform for neoantigen identification
Analytical platform and workflows to identify biomarkers and candidate neoantigens to enable personalized vaccine development and other targeted immunotherapies.
NeXT Personal® Dx
An ultra-sensitive tumor-informed liquid biopsy assay designed to detect molecular residual disease (MRD) at ultra-low levels, track responses to therapy, and identify clinically relevant variants.
ImmunoID NeXT
ImmunoID NeXT combines multiple biomarker assays into one, simultaneously solving logistical and technical problems for clinical trial sponsors by elucidating tumor-immune interactions from a single sample.
ACE ImmunoID
ACE ImmunoID is an analytically-validated whole exome and transcriptome sequencing platform using matched tumor and normal samples, developed for use with our RUO neoantigen prediction analysis pipeline.
Services
Laboratory testing services for ctDNA MRD monitoring and tumor genomic profiling provided through an accredited clinical laboratory.
Assay development, validation and deployment services to support biomarker strategies and clinical study endpoints in collaboration with biopharma partners.
Data processing, variant calling, and analytics pipelines for interpretation of tumor and cfDNA sequencing used for personalized panel design and clinical reporting.
Laboratory testing services for ctDNA MRD monitoring and tumor genomic profiling provided through an accredited clinical laboratory.
Assay development, validation and deployment services to support biomarker strategies and clinical study endpoints in collaboration with biopharma partners.
Data processing, variant calling, and analytics pipelines for interpretation of tumor and cfDNA sequencing used for personalized panel design and clinical reporting.
Expertise Areas
- Liquid biopsy and ctDNA MRD detection
- Comprehensive tumor genomic profiling
- Bioinformatics and clinical analytics
- Biomarker discovery and neoantigen analysis
Key Technologies
- Next-generation sequencing (NGS)
- Whole-genome sequencing (WGS)
- Tumor-informed personalized ctDNA panels
- Ultra-low limit-of-detection ctDNA assays (single-digit PPM)
News & Updates
Agreement to use whole‑genome sequencing–based assays in clinical studies evaluating an individualized neoantigen mRNA therapy.
Regulatory milestone enabling clinical use of an ultrasensitive MRD test in Great Britain.
Presentations reporting ultrasensitive MRD performance across multiple solid tumor types and early recurrence detection in colorectal cancer cohorts.
Analytical validation studies and manuscripts describing assay performance and analytical methods in peer‑reviewed journals and conference proceedings.
Agreement to use whole‑genome sequencing–based assays in clinical studies evaluating an individualized neoantigen mRNA therapy.
Regulatory milestone enabling clinical use of an ultrasensitive MRD test in Great Britain.
Presentations reporting ultrasensitive MRD performance across multiple solid tumor types and early recurrence detection in colorectal cancer cohorts.
Analytical validation studies and manuscripts describing assay performance and analytical methods in peer‑reviewed journals and conference proceedings.